Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P16452
UPID:
EPB42_HUMAN
Alternative names:
Erythrocyte membrane protein band 4.2
Alternative UPACC:
P16452; Q4KKX0; Q4VB97
Background:
Protein 4.2, also known as Erythrocyte membrane protein band 4.2, plays a crucial role as part of the ankyrin-1 complex. This complex is essential for maintaining the stability and shape of the erythrocyte membrane, ensuring proper cellular function.
Therapeutic significance:
Given its pivotal role in erythrocyte membrane integrity, Protein 4.2's dysfunction is directly linked to Spherocytosis 5, a condition characterized by chronic hemolytic anemia and abnormally shaped erythrocytes. Targeting Protein 4.2 could offer novel therapeutic avenues for managing this hematologic disorder.